# U.S. Recruitment for Ohio State University Study Evaluating EmeTerm in Adults With Chronic Nausea and Vomiting

- Link: https://www.thailand-business-news.com/pr-news/u-s-recruitment-for-ohio-state-university-study-evaluating-emeterm-in-adults-with-chronic-nausea-and-vomiting
- Published: 2026-08-17T20:00:00+07:00
- Author: PR Newswire

VANCOUVER, BC, Aug. 17, 2026 /PRNewswire/ — Participant recruitment information 
for a clinical study being conducted at The Ohio State University has been publicly
posted on ClinicalTrials.gov. The study, titled "Evaluating the Effect of Wearing
a TENS Device in Nausea Relief," is also known as the WINNER Study. It is registered
under ClinicalTrials.gov identifier NCT07720323 and is currently listed as recruiting.
The study is sponsored by The Ohio State University and is expected to enroll approximately
120 adults.

ClinicalTrials.gov is a public registry and results database for clinical research
studies. It was developed and is supported by the U.S. National Library of Medicine,
part of the National Institutes of Health, to make information about ongoing and
completed clinical studies accessible to patients, healthcare professionals and 
researchers.

**Understanding Cyclic Vomiting Syndrome and Chronic Nausea**

Cyclic vomiting syndrome, commonly known as CVS, is a disorder characterized by 
sudden and repeated episodes of severe nausea and vomiting. Episodes may last from
several hours to several days and are typically separated by longer periods during
which the person experiences few or no symptoms. The recurring and unpredictable
nature of CVS can significantly disrupt work, education, daily activities and overall
quality of life.

CVS is one condition within the broader spectrum of disorders involving recurrent
or persistent nausea and vomiting. Some patients may experience chronic nausea between
vomiting episodes, while others may have persistent nausea associated with abdominal
pain, bloating, constipation, reduced appetite, fatigue, sleep disturbance or other
gastrointestinal symptoms.

**About the WINNER Study**

The WINNER (WearINg a TENS-device in Nausea Relief) Study is a single-center clinical
trial conducted at The Ohio State University to evaluate the effectiveness of the
EmeTerm wearable TENS device in adults with nausea that has persisted for more than
2 months.

EmeTerm is a wearable transcutaneous electrical nerve stimulation device, worn around
the wrist and delivers controlled electrical stimulation to the median nerve. The
study will examine whether using the device reduces the average weekly frequency
of moderate-to-severe nausea compared with symptoms recorded before device use. 
Researchers will also assess changes in vomiting frequency, nausea duration, use
of anti-nausea medication and other aspects of gastrointestinal health and general
wellbeing.

The study is a single-group trial without a placebo arm. Each participant will serve
as their own comparison, with symptoms during the 12-week device-use period compared
with symptoms documented during the preceding two-week baseline period.

The primary outcome is the change in the average weekly number of days on which 
participants experience moderate or severe nausea. Secondary outcomes include changes
in vomiting frequency and the use of anti-nausea medications. The study will also
explore possible changes in abdominal pain, bloating, constipation, appetite, sleep,
mood, stress, fatigue, quality of life and hope.

[[

**Who May Be Eligible to Participate**

According to the ClinicalTrials.gov recruitment listing, potential participants 
must meet the following principal requirements:

 ◦ Be 18 years of age or older;
 ◦ Have experienced nausea for more than two months;
 ◦ Be able to understand English;
 ◦ Be receiving care at The Ohio State University; and
 ◦ Be able to complete electronic questionnaires using a smartphone or computer.

The study does not accept healthy volunteers. Final eligibility will be determined
by the study team following screening.

**Invitation to Potential Participants**

Adults experiencing persistent nausea, recurrent vomiting or related gastrointestinal
symptoms who currently receive care at The Ohio State University may review the 
official study information and speak with their healthcare provider about whether
participation may be appropriate.

Individuals who believe they may meet the eligibility requirements can search for
NCT07720323 on ClinicalTrials.gov to review the full study description, current 
recruitment status, study location and official contact information. For additional
information about the study, interested individuals may contact the study team directly
at [Subhankar.chakraborty@osumc.edu](https://www.thailand-business-news.com/pr-news/Subhankar.chakraborty@osumc.edu).

**About WAT Medical and EmeTerm**

WAT Medical Enterprise Ltd. is a medical technology company specializing in wearable
neuromodulation technologies, with more than 10 years of research and development
experience focused on targeted nerve stimulation. The company develops non-invasive
wearable technologies designed to support symptom management across areas including
nausea, motion sickness and migraine.

EmeTerm is WAT Medical’s wearable anti-nausea device based on Transcutaneous Electrical
Acupoint Stimulation (TEAS) technology. Designed to deliver controlled electrical
stimulation at the wrist, EmeTerm is FDA cleared and provides a non-pharmacological
approach to nausea and vomiting relief.

EmeTerm is supported by clinical research and independent peer-reviewed studies,
including research published in JAMA Surgery and the British Journal of Anaesthesia(
BJA). EmeTerm has also achieved strong consumer recognition, ranking as the No. 
1 best-selling medical-grade wearable anti-nausea device on Amazon and receiving
consistently positive reviews from users. WAT Medical continues to advance targeted
neuromodulation technologies through ongoing research and clinical collaboration.

**References**

 1. [https://clinicaltrials.gov/study/NCT07720323?term=EMETERM&rank=1](https://clinicaltrials.gov/study/NCT07720323?term=EMETERM&rank=1)
 2. Zheng D, Ding P, Gong M, et al. (2026). Transcutaneous Electrical Acupoint Stimulation
    vs Metoclopramide for Moderate to Severe Postoperative Nausea and Vomiting: A Randomized
    Clinical Trial. JAMA Surg. doi:10.1001/jamasurg.2025.6394
 3. Wang, N., et al. (2022). Wearable transcutaneous electrical acupoint stimulation
    bracelet for prevention of postoperative nausea and vomiting in patients undergoing
    hysteroscopic surgery: a randomised controlled trial. British Journal of Anaesthesia,
    129(4), e85-e87.
 4. [www.emeterm.com](http://www.emeterm.com/)
 5. [www.watmedical.com](http://www.watmedical.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [U.S. Recruitment for Ohio State University Study Evaluating EmeTerm in Adults With Chronic Nausea and Vomiting ](http://www.prnasia.com/story/archive/5027216_CN27216_0?rand=184833)
